Literature DB >> 24704314

Phosphorylation of protein Tau by GSK3β prolongs survival of bigenic Tau.P301L×GSK3β mice by delaying brainstem tauopathy.

Natalia Crespo-Biel1, Clara Theunis1, Peter Borghgraef1, Benoit Lechat1, Herman Devijver1, Hervé Maurin1, Fred Van Leuven2.   

Abstract

Tau.P301L transgenic mice suffer precocious mortality between ages 8 and 11 months, resulting from upper airway defects caused by tauopathy in autonomic brainstem circuits that control breathing (Dutschmann et al., 2010). In individual mice, the clinical phenotype evolves progressively and rapidly (3-6weeks) from clasping, over general motor impairment to severe reduction in body-weight into the terminal phase that announces imminent death (<3days). Surprisingly, co-expression of GSK3β with Tau.P301L significantly prolonged survival of bigenic biGT mice (Terwel et al., 2008), which we here assign to delayed development of brainstem tauopathy. Eventually, brainstem tauopathy became as prominent in old biGT mice in the specified brainstem nuclei as in the parental Tau.P301L mice, resulting in similar clinical deterioration and terminal phase preceding death, although at later age. Biochemically, in both genotypes the pathway to neurofibrillary tangles and neuropil threads was similar: phosphorylation of protein Tau and formation of soluble oligomers and insoluble aggregates, ending in the typical tangles and threads of tauopathy. The extra GSK3β activity led to expected increased phosphorylation of protein Tau, particularly at residues S262 and S396, which we must conclude to delay the aggregation of protein Tau in the brainstem of aging biGT mice. The unexpected, paradoxical alleviation of the brainstem problems in biGT mice allowed them to grow older and thereby develop more severe tauopathy in forebrain than Tau.P301L mice, which succumb at younger age.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brainstem; GSK3; Protein Tau; Survival; Tauopathy

Mesh:

Substances:

Year:  2014        PMID: 24704314     DOI: 10.1016/j.nbd.2014.03.016

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

1.  Silencing of the Drosophila ortholog of SOX5 leads to abnormal neuronal development and behavioral impairment.

Authors:  Airong Li; Basavaraj Hooli; Kristina Mullin; Rebecca E Tate; Adele Bubnys; Rory Kirchner; Brad Chapman; Oliver Hofmann; Winston Hide; Rudolph E Tanzi
Journal:  Hum Mol Genet       Date:  2017-04-15       Impact factor: 6.150

2.  Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.

Authors:  Zigao Wang; Lu Xiong; Wenbin Wan; Lijie Duan; Xiaojing Bai; Hengbing Zu
Journal:  Front Mol Neurosci       Date:  2017-02-08       Impact factor: 5.639

3.  Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope.

Authors:  Clara Theunis; Oskar Adolfsson; Natalia Crespo-Biel; Kasia Piorkowska; Maria Pihlgren; David T Hickman; Valérie Gafner; Peter Borghgraef; Herman Devijver; Andrea Pfeifer; Fred Van Leuven; Andreas Muhs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology.

Authors:  Ana I Rojo; Marta Pajares; Patricia Rada; Angel Nuñez; Alejo J Nevado-Holgado; Richard Killik; Fred Van Leuven; Elena Ribe; Simon Lovestone; Masayuki Yamamoto; Antonio Cuadrado
Journal:  Redox Biol       Date:  2017-07-05       Impact factor: 11.799

5.  Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy.

Authors:  Ana I Rojo; Marta Pajares; Angel J García-Yagüe; Izaskun Buendia; Fred Van Leuven; Masayuki Yamamoto; Manuela G López; Antonio Cuadrado
Journal:  Redox Biol       Date:  2018-07-11       Impact factor: 11.799

6.  Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.

Authors:  Nicholas J Izzo; Carla M Yuede; Kelsie M LaBarbera; Colleen S Limegrover; Courtney Rehak; Raymond Yurko; Lora Waybright; Gary Look; Gilbert Rishton; Hank Safferstein; Mary E Hamby; Claire Williams; Kelsey Sadlek; Hannah M Edwards; Charles S Davis; Michael Grundman; Lon S Schneider; Steven T DeKosky; Daniel Chelsky; Ian Pike; Christopher Henstridge; Kaj Blennow; Henrik Zetterberg; Harry LeVine; Tara L Spires-Jones; John R Cirrito; Susan M Catalano
Journal:  Alzheimers Dement       Date:  2021-02-08       Impact factor: 21.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.